Western Medicine Lincomycin Hydrochloride for Human Use

Product Details
Customization: Available
Application: Internal Medicine
Usage Mode: For external use
Gold Member Since 2020

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

QA/QC Inspectors
The supplier has 1 QA and QC inspection staff
100% Finished Products Inspection
The supplier inspects 100% of finished products.
Standardized quality control
The supplier has a complete and standardized quality control process, check the Audit Report for more information
R&D Capabilities
The supplier has 1 R&D engineers, you can check the Audit Report for more information
to see all verified strength labels (12)
  • Western Medicine Lincomycin Hydrochloride for Human Use
  • Western Medicine Lincomycin Hydrochloride for Human Use
  • Western Medicine Lincomycin Hydrochloride for Human Use
  • Western Medicine Lincomycin Hydrochloride for Human Use
  • Western Medicine Lincomycin Hydrochloride for Human Use
  • Western Medicine Lincomycin Hydrochloride for Human Use
Find Similar Products
  • Overview
  • Company Profile
  • Product Description
  • After Sales Service
Overview

Basic Info.

Model NO.
injection
State
Liquid
Shape
Injection
Type
Organic Chemicals
Pharmaceutical Technology
Chemical Synthesis
Dosage
600mg/2ml
Use
Injection
Package
Ampoules/
Vial
Yes
Transport Package
Box
Specification
600mg
Origin
China
Production Capacity
500000box/Month

Product Description

Western Medicine Lincomycin Hydrochloride for Human Use
Company Profile
DMS is a leading pharmaceutical Contract Development and Manufacturing Organizations (CDMO).
DMS's Manufacturing Services supply several hundred different products in a variety of dosage forms including solid dose, semi solids, sterile (liquids, freeze dried,powder), beta-lactams, hormones, dry powder metered dose inhalers, oral liquids and granulates, from our facilities across the world.
Product Description

 

Product Name Lincomycin Injection
Contains Lincomycin Hydrochloride 600mg
Package 5amps/box
store Below 30C
Application Antibiotic
CLINICAL PHARMACOLOGY
ntramuscular administration of a single dose of 600 mg of lincomycin produces average peak serum levels of 11.6 µg/mL at 60 minutes and maintains therapeutic levels for 17 to 20 hours for most susceptible gram-positive organisms. Urinary excretion after this dose ranges from 1.8 to 24.8 percent (mean: 17.3 percent).
A two hour intravenous infusion of 600 mg of lincomycin achieves average peak serum levels of 15.9 µg/mL and yields therapeutic levels for 14 hours for most susceptible gram-positive organisms. Urinary excretion ranges from 4.9 to 30.3 percent (mean: 13.8 percent).
The biological half-life after intramuscular or intravenous administration is 5.4 ± 1.0 hours. The serum half-life of lincomycin may be prolonged in patients with severe impairment of renal function compared to patients with normal renal function. In patients with abnormal hepatic function, serum half-life may be twofold longer than in patients with normal hepatic function. Hemodialysis and peritoneal dialysis are not effective in removing lincomycin from the serum.
Tissue level studies indicate that bile is an important route of excretion. Significant levels have been demonstrated in the majority of body tissues. Although lincomycin appears to diffuse into cerebrospinal fluid (CSF), levels of lincomycin in the CSF appear inadequate for the treatment of meningitis.
Microbiology
Lincomycin has been shown to be active against most strains of the following organisms both in vitro and in clinical infections: (see INDICATIONS AND USAGE).
  Staphylococcus aureus
  Streptococcus pneumoniae
The following in vitro data are available; but their clinical significance is unknown.
Lincomycin has been shown to be active in vitro against the following microorganisms; however, the safety and efficacy of Lincomycin in treating clinical infections due to these organisms have not been established in adequate and well controlled trials.
Gram-positive bacteria::
  Corynebacterium diphtheriae
  Streptococcus pyogenes
  Viridans group streptococci
Anaerobic bacteria:
  Clostridium tetani
 
 Resistance is most often due to methylation of specific nucleotides in the 23S RNA of the 50S ribosomal subunit, which can determine cross resistance to macrolides and streptogramins B (MLSB phenotype). Macrolide-resistant isolates of these organisms should be tested for inducible resistance to lincomycin/clindamycin using the D-zone test or other appropriate method.
There are currently no antimicrobial susceptibility testing (AST) interpretive criteria for Lincomycin
After Sales Service
1. Mixed container, we can mix different items in one container.
2. Quality control, before shipment, free sample for test. After shipment, keep sample for 3 years
3. Prompt shipment with professional documents
4. Packing as your request, with photo before shipment.
Western Medicine Lincomycin Hydrochloride for Human Use Western Medicine Lincomycin Hydrochloride for Human Use Western Medicine Lincomycin Hydrochloride for Human Use
Western Medicine Lincomycin Hydrochloride for Human Use Western Medicine Lincomycin Hydrochloride for Human Use Western Medicine Lincomycin Hydrochloride for Human Use
Western Medicine Lincomycin Hydrochloride for Human Use Western Medicine Lincomycin Hydrochloride for Human Use Western Medicine Lincomycin Hydrochloride for Human Use

 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier